Gilead Sciences (0QYQ) Share Forecast & Price Target

3 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0QYQ Analyst Ratings

Strong Buy

17 Buy

5 Hold

0 Sell

Based on 22 analysts giving stock ratings to

Gilead

Sciences

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0QYQ Stock 12 Month Forecast

Average Price Target

$171.81

▲(15.33% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is $171.81 with a high forecast of $200.00 and a low forecast of $129.00. The average price target represents a 15.33% change from the last price of $148.97.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"108":"$108","201":"$201","131.25":"$131.3","154.5":"$154.5","177.75":"$177.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":171.8095238095238,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$171.81</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":129,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$129.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[108,131.25,154.5,177.75,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2026","6":"Apr<br/>2026","9":"Jul<br/>2026","12":"Oct<br/>2026","25":"Oct<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,148.04,152.03692307692307,156.03384615384616,160.03076923076924,164.0276923076923,168.02461538461537,172.02153846153846,176.01846153846154,180.01538461538462,184.01230769230767,188.00923076923078,192.00615384615384,196.00307692307692,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,148.04,149.8684249084249,151.6968498168498,153.52527472527473,155.35369963369962,157.18212454212454,159.01054945054943,160.83897435897435,162.66739926739925,164.49582417582417,166.32424908424906,168.15267399267398,169.9810989010989,{"y":171.8095238095238,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,148.04,146.57538461538462,145.11076923076922,143.64615384615385,142.18153846153845,140.71692307692308,139.25230769230768,137.7876923076923,136.3230769230769,134.85846153846154,133.39384615384614,131.92923076923077,130.4646153846154,{"y":129,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":109.384,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":116.784,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":121.496,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":120.912,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.831,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":147.397,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":139.268,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":130.27,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.429,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 58,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":125.29,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":129.975,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.121,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":148.04,"date":1790812800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 52,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$200.00

Average Price Target$171.81

Lowest Price Target$129.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Tyler Van Buren

TD Cowen

$160→$175

Buy

17.47%

Upside

Reiterated

10/30/26

Gilead Sciences (GILD) Receives a Rating Update from a Top Analyst

Joseph Stringer

Needham

$170→$200

Buy

34.26%

Upside

Reiterated

10/30/26

Needham Sticks to Their Buy Rating for Gilead Sciences (GILD)

Geoff Meacham

Citi

$165→$188

Buy

26.20%

Upside

Reiterated

10/30/26

Gilead price target raised to $188 from $165 at CitiGilead price target raised to $188 from $165 at Citi

Gregory Renza

Truist Financial

$158→$181

Buy

21.50%

Upside

Reiterated

10/30/26

Gilead price target raised to $181 from $158 at TruistGilead price target raised to $181 from $158 at Truist

Evan Seigerman

BMO Capital

$174→$184

Buy

23.51%

Upside

Reiterated

10/30/26

BMO Capital Sticks to Their Buy Rating for Gilead Sciences (GILD)

Mohit Bansal

Wells Fargo

$165→$190

Buy

27.54%

Upside

Assigned

10/30/26

Analysts Are Bullish on These Healthcare Stocks: Gilead Sciences (GILD), Encompass Health (EHC)

Terence Flynn

Morgan Stanley

$163→$183

Buy

22.84%

Upside

Assigned

10/30/26

Gilead Sciences (GILD) Receives a Buy from Morgan Stanley

Louise Chen

Scotiabank

$177→$200

Buy

34.26%

Upside

Reiterated

10/30/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Bristol-Myers Squibb (NYSE: BMY) and Sarepta Therapeutics (NASDAQ: SRPT)

Chris Schott

J.P. Morgan

$170→$190

Buy

27.54%

Upside

Assigned

10/30/26

Gilead price target raised to $190 from $170 at JPMorganGilead price target raised to $190 from $170 at JPMorgan

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

10/30/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Viridian Therapeutics (NASDAQ: VRDN), Align Tech (NASDAQ: ALGN) and Gilead Sciences (NASDAQ: GILD)

Michael Yee

UBS

$175→$195

Buy

30.90%

Upside

Assigned

10/30/26

Gilead price target raised to $195 from $175 at UBSGilead price target raised to $195 from $175 at UBS

Brian Abrahams

RBC Capital

$126→$131

Hold

-12.06%

Downside

Reiterated

10/29/26

RBC Capital Reaffirms Their Hold Rating on Gilead Sciences (GILD)

Salveen Richter

Goldman Sachs

$142→$155

Hold

4.05%

Upside

Reiterated

10/29/26

Goldman Sachs Keeps Their Hold Rating on Gilead Sciences (GILD)

Carter Gould

Cantor Fitzgerald

$155→$175

Buy

17.47%

Upside

Reiterated

10/29/26

Gilead price target raised to $175 from $155 at Cantor FitzgeraldGilead price target raised to $175 from $155 at Cantor Fitzgerald

Emily Field

Barclays

$145

Hold

-2.66%

Downside

Reiterated

10/28/26

Analysts Offer Insights on Healthcare Companies: Icon (NASDAQ: ICLR), Centene (NYSE: CNC) and Gilead Sciences (NASDAQ: GILD)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Tyler Van Buren

TD Cowen

$160→$175

Buy

17.47%

Upside

Reiterated

10/30/26

Gilead Sciences (GILD) Receives a Rating Update from a Top Analyst

Joseph Stringer

Needham

$170→$200

Buy

34.26%

Upside

Reiterated

10/30/26

Needham Sticks to Their Buy Rating for Gilead Sciences (GILD)

Geoff Meacham

Citi

$165→$188

Buy

26.20%

Upside

Reiterated

10/30/26

Gilead price target raised to $188 from $165 at CitiGilead price target raised to $188 from $165 at Citi

Gregory Renza

Truist Financial

$158→$181

Buy

21.50%

Upside

Reiterated

10/30/26

Gilead price target raised to $181 from $158 at TruistGilead price target raised to $181 from $158 at Truist

Evan Seigerman

BMO Capital

$174→$184

Buy

23.51%

Upside

Reiterated

10/30/26

BMO Capital Sticks to Their Buy Rating for Gilead Sciences (GILD)

Mohit Bansal

Wells Fargo

$165→$190

Buy

27.54%

Upside

Assigned

10/30/26

Analysts Are Bullish on These Healthcare Stocks: Gilead Sciences (GILD), Encompass Health (EHC)

Terence Flynn

Morgan Stanley

$163→$183

Buy

22.84%

Upside

Assigned

10/30/26

Gilead Sciences (GILD) Receives a Buy from Morgan Stanley

Louise Chen

Scotiabank

$177→$200

Buy

34.26%

Upside

Reiterated

10/30/26

Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Bristol-Myers Squibb (NYSE: BMY) and Sarepta Therapeutics (NASDAQ: SRPT)

Chris Schott

J.P. Morgan

$170→$190

Buy

27.54%

Upside

Assigned

10/30/26

Gilead price target raised to $190 from $170 at JPMorganGilead price target raised to $190 from $170 at JPMorgan

Umer Raffat

Evercore ISI

―

Buy

―

Reiterated

10/30/26

Analysts' Opinions Are Mixed on These Healthcare Stocks: Viridian Therapeutics (NASDAQ: VRDN), Align Tech (NASDAQ: ALGN) and Gilead Sciences (NASDAQ: GILD)

Michael Yee

UBS

$175→$195

Buy

30.90%

Upside

Assigned

10/30/26

Gilead price target raised to $195 from $175 at UBSGilead price target raised to $195 from $175 at UBS

Brian Abrahams

RBC Capital

$126→$131

Hold

-12.06%

Downside

Reiterated

10/29/26

RBC Capital Reaffirms Their Hold Rating on Gilead Sciences (GILD)

Salveen Richter

Goldman Sachs

$142→$155

Hold

4.05%

Upside

Reiterated

10/29/26

Goldman Sachs Keeps Their Hold Rating on Gilead Sciences (GILD)

Carter Gould

Cantor Fitzgerald

$155→$175

Buy

17.47%

Upside

Reiterated

10/29/26

Gilead price target raised to $175 from $155 at Cantor FitzgeraldGilead price target raised to $175 from $155 at Cantor Fitzgerald

Emily Field

Barclays

$145

Hold

-2.66%

Downside

Reiterated

10/28/26

Analysts Offer Insights on Healthcare Companies: Icon (NASDAQ: ICLR), Centene (NYSE: CNC) and Gilead Sciences (NASDAQ: GILD)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AMRXAmneal Pharmaceuticals

DNTHDianthus Therapeutics

REPLReplimune Group

VSTMVerastem

OVIDOvid Therapeutics

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Gilead Sciences

3 Months

Courtney BreenBernstein

Success Rate

17/21 ratings generated profit

Average Return

+8.08%

Copying Courtney Breen's trades and holding each position for 3 Months would result in 80.95% of your transactions generating a profit, with an average return of +8.08% per trade.

1 Year

Geoff MeachamCiti

Success Rate

26/26 ratings generated profit

Average Return

+31.70%

Copying Geoff Meacham's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +31.70% per trade.

2 Years

Chris SchottJ.P. Morgan

Success Rate

26/26 ratings generated profit

Average Return

+58.99%

Copying Chris Schott's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +58.99% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0QYQ Analyst Recommendation Trends

Rating

Jun 26

Jul 26

Aug 26

Sep 26

Oct 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0QYQ has received 52 Buy Ratings, 12 Hold Ratings, and 0 Sell Ratings. 0QYQ average Analyst price target in the past 3 months is 171.81.

Each month's total comprises the sum of three months' worth of ratings.

0QYQ Financial Forecast

0QYQ Earnings Forecast

Next quarter’s earnings estimate for 0QYQ is $1.39 with a range of $0.92 to $2.33. The previous quarter’s EPS was $2.55. 0QYQ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0QYQ has Performed in-line its overall industry.

0QYQ Sales Forecast

Next quarter’s sales forecast for 0QYQ is $8.28B with a range of $8.03B to $8.53B. The previous quarter’s sales results were $8.30B. 0QYQ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0QYQ has Performed in-line its overall industry.

0QYQ Stock Forecast FAQ

What is GB:0QYQ’s average 12-month price target, according to analysts?

Based on analyst ratings, Gilead Sciences’s 12-month average price target is 171.81.

What is GB:0QYQ’s upside potential, based on the analysts’ average price target?

Gilead Sciences has 15.33% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Gilead Sciences a Buy, Sell or Hold?

Gilead Sciences has a consensus rating of Strong Buy, which is based on 17 buy ratings, 5 hold ratings and 0 sell ratings.

What is Gilead Sciences’s share price target?

The average share price target for Gilead Sciences is 171.81. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $200.00 ,and the lowest forecast is $129.00. The average share price target represents 15.33% Increase from the current price of $148.97.

What do analysts say about Gilead Sciences?

Gilead Sciences’s analyst rating consensus is a Strong Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of Gilead Sciences?

To buy shares of GB:0QYQ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Gilead Sciences (0QYQ) Share Forecast & Price Target

0QYQ Analyst Ratings

0QYQ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Gilead Sciences

0QYQ Analyst Recommendation Trends

0QYQ Financial Forecast

0QYQ Earnings Forecast

0QYQ Sales Forecast

0QYQ Stock Forecast FAQ

Detailed List of Analyst Forecasts